Keytruda, also known as pembrolizumab, is a type of immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1, which helps cancer cells avoid being attacked by the immune system. Keytruda is currently approved by the FDA to treat several types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial carcinoma, and gastric cancer [2].

According to a study published in the New England Journal of Medicine, Keytruda has been shown to be effective in treating advanced melanoma. In the study, patients who received Keytruda had a higher response rate and longer progression-free survival than those who received chemotherapy [3]. Another study found that Keytruda was effective in treating advanced non-small cell lung cancer, with patients experiencing a longer overall survival rate than those who received chemotherapy [1].

However, like all drugs, Keytruda does have potential side effects. The most common side effects include fatigue, nausea, and loss of appetite. More serious side effects, such as immune-related adverse events, can occur as well [2]. It is important for patients to discuss the potential benefits and risks of Keytruda with their doctor.

In conclusion, Keytruda has shown to be effective in treating various types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial carcinoma, and gastric cancer. However, like all drugs, it does have potential side effects that should be discussed with a doctor.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
[3] https://www.medicalnewstoday.com/articles/keytruda